Loading...
XSTO
SPAGO
Market cap7mUSD
May 28, Last price  
0.20SEK
1D
-15.00%
1Q
2.00%
Jan 2017
-98.48%
IPO
-98.26%
Name

Spago Nanomedical AB (publ)

Chart & Performance

D1W1MN
P/E
—
P/S
37.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
72.93%
Rev. gr., 5y
129.52%
Revenues
2m
+58.85%
981,000222,000228,00054,0007,515,00058,00047,00029,644,00030,000342,000660,0001,054,0001,203,0001,911,000
Net income
-33m
L-23.01%
-715,000-4,615,000-5,214,000-6,131,000-6,791,000-7,540,000-9,457,000-11,092,000-20,280,000-18,903,000-39,075,000-39,309,000-42,223,000-32,509,000
CFO
-35m
L-22.80%
-276,000-601,000-7,737,000-5,952,000-5,345,000-7,863,000-7,730,000-10,510,000-21,288,000-18,766,000-35,569,000-38,187,000-44,909,000-34,668,000

Profile

Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
URL
https://spagonanomedical.se/
IPO date
Jan 15, 2013
Employees
13
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,911
58.85%
1,203
14.14%
1,054
59.70%
Cost of revenue
14,269
24,486
41,828
Unusual Expense (Income)
NOPBT
(12,358)
(23,283)
(40,774)
NOPBT Margin
Operating Taxes
112
Tax Rate
NOPAT
(12,358)
(23,283)
(40,886)
Net income
(32,509)
-23.01%
(42,223)
7.41%
(39,309)
0.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
28,530
51,657
BB yield
-89.05%
-122.73%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
2,271,504
191
4,725
Net debt
(32,470)
(45,370)
(62,102)
Cash flow
Cash from operating activities
(34,668)
(44,909)
(38,187)
CAPEX
(153)
(3,829)
Cash from investing activities
(230)
(506)
(3,829)
Cash from financing activities
22,152
28,530
51,657
FCF
(12,300)
(23,355)
(40,664)
Balance
Cash
32,470
45,217
62,101
Long term investments
153
1,000
Excess cash
32,374
45,310
62,049
Stockholders' equity
3,482
(229,242)
(59,990)
Invested Capital
30,238
270,750
257,146
ROIC
ROCE
EV
Common stock shares outstanding
348,196
97,978
66,808
Price
0.20
-40.06%
0.33
-48.10%
0.63
-86.88%
Market cap
68,246
113.01%
32,039
-23.88%
42,089
-79.04%
EV
35,776
(13,331)
(20,013)
EBITDA
(12,358)
(23,002)
(40,418)
EV/EBITDA
0.58
0.50
Interest
268
Interest/NOPBT